KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Aquestive Therapeutics (AQST) Receivables - Other (2017 - 2025)

Aquestive Therapeutics (AQST) has 8 years of Receivables - Other data on record, last reported at $9.8 million in Q4 2025.

  • For Q4 2025, Receivables - Other rose 1586.85% year-over-year to $9.8 million; the TTM value through Dec 2025 reached $9.8 million, up 1586.85%, while the annual FY2025 figure was $9.8 million, 1586.85% up from the prior year.
  • Receivables - Other reached $9.8 million in Q4 2025 per AQST's latest filing, up from $2.3 million in the prior quarter.
  • Across five years, Receivables - Other topped out at $9.8 million in Q4 2025 and bottomed at $578000.0 in Q4 2024.
  • Average Receivables - Other over 5 years is $2.6 million, with a median of $2.2 million recorded in 2022.
  • Peak YoY movement for Receivables - Other: tumbled 80.17% in 2024, then surged 1586.85% in 2025.
  • A 5-year view of Receivables - Other shows it stood at $6.0 million in 2021, then tumbled by 64.35% to $2.1 million in 2022, then surged by 36.28% to $2.9 million in 2023, then crashed by 80.17% to $578000.0 in 2024, then skyrocketed by 1586.85% to $9.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Receivables - Other were $9.8 million in Q4 2025, $2.3 million in Q3 2025, and $645000.0 in Q2 2025.